Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B

Safe and effective vaccines are needed to end the COVID-19 pandemic. Here, we report the preclinical development of a lipid nanoparticle–formulated SARS-CoV-2 mRNA vaccine, PTX-COVID19-B. PTX-COVID19-B was chosen among three candidates after the initial mouse vaccination results showed that it elici...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jun, Budylowski, Patrick, Samson, Reuben, Griffin, Bryan D., Babuadze, Giorgi, Rathod, Bhavisha, Colwill, Karen, Abioye, Jumai A., Schwartz, Jordan A., Law, Ryan, Yip, Lily, Ahn, Sang Kyun, Chau, Serena, Naghibosadat, Maedeh, Arita, Yuko, Hu, Queenie, Yue, Feng Yun, Banerjee, Arinjay, Hardy, W. Rod, Mossman, Karen, Mubareka, Samira, Kozak, Robert A., Pollanen, Michael S., Martin Orozco, Natalia, Gingras, Anne-Claude, Marcusson, Eric G., Ostrowski, Mario A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769538/
https://www.ncbi.nlm.nih.gov/pubmed/35044832
http://dx.doi.org/10.1126/sciadv.abj9815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769538/
https://www.ncbi.nlm.nih.gov/pubmed/35044832
http://dx.doi.org/10.1126/sciadv.abj9815

Ejemplares similares